FY2019 · ended Dec 31, 2019 · Revenue $39.91M, -7.2% YoY · Filed Apr 1, 2021
Enveric Biosciences, Inc. (ENVB) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue (TTM)
$35.41M
-13.9% vs year-ago TTM
Net income (TTM)
$-1.82M
+92.0% vs year-ago TTM
Operating cash flow (TTM)
$-8.56M
-31.3% vs year-ago TTM
Free cash flow
$-14.10M
+20.5% vs prior year
EPS (TTM)
$-1.94
-208.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
1.89M
-23.6% vs prior year
Net cash
$17.66M
FY 2022
Operating margin
-0.1%
FY 2020
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ENVB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 890821
- Former names
- AMERI Holdings, Inc. (until Dec 30, 2020); SPATIALIZER AUDIO LABORATORIES INC (until May 27, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$8.8M | -$9.6M | -$16.4M | -$27.4M | -$64.6M |
| Net income | -$8.8M | -$9.6M | -$17.3M | -$18.5M | -$49.0M |
| Diluted EPS | -$36.24 | -$228.48 | -$121.29 | — | — |
| Operating cash flow | -$8.1M | -$7.7M | -$14.1M | -$17.1M | -$11.5M |
| Free cash flow | — | — | -$14.1M | -$17.7M | — |
| Total assets | $5.1M | $3.1M | $4.3M | $19.6M | $26.7M |
| Total liabilities | — | — | — | $4.0M | $4.4M |
| Stockholders' equity | $4.2M | $1.6M | $2.0M | $14.7M | $22.3M |
| Cash and investments | $4.7M | $2.2M | $2.3M | $17.7M | $17.4M |
| Total debt | — | — | — | $63,820 | $176,303 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Other events
|
Jun 9, 2026 | Jun 9, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 9, 2026 | Jun 8, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 29, 2026 | May 22, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
All 1000 Enveric Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.